BOSTON, Oct. 21 - As traditional robotics approaches the limits of its usefulness in drug discovery, biotech and pharma companies, beset by shrunken pipelines and pressed for time, have set their sites on a new breed of lab automation.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
The first Reproducibility Project: Cancer Biology papers show mixed results.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.